title: Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent alpha-glucosidase and alpha-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice.
abstract: This study was designed to investigate whether diphlorethohydroxycarmalol (DPHC) may inhibit alpha-glucosidase and alpha-amylase activities, and alleviate postprandial hyperglycemia in streptozotocin-induced diabetic mice. DPHC isolated from Ishige okamurae, a brown algae, evidenced prominent inhibitory effect against alpha-glucosidase and alpha-amylase. The IC(50) values of DPHC against alpha-glucosidase and alpha-amylase were 0.16 and 0.53 mM, respectively, which evidenced the higher activities than that of acarbose. DPHC did not exert any cytotoxic effect in human umbilical vein endothelial cells (HUVECs) at various concentrations (from 0.49 to 3.91 mM). The increase of postprandial blood glucose levels were significantly suppressed in the DPHC-administered group than those in the streptozotocin-induced diabetic or normal mice. Moreover, the area under curve (AUC) was significantly reduced via DPHC administration (2022 versus 2210 mmol x min/l) in the diabetic mice as well as it delays absorption of dietary carbohydrates. Therefore, these result indicated that DPHC might be a potent inhibitor for alpha-glucosidase and alpha-amylase.
authors.affiliation: Marine Living Resources Research Department, Korea Ocean Research & Development Institute, Ansan, 426-744, South Korea.
authors.forename: Soo-Jin
authors.initials: SJ
authors.lastname: Heo
authors.forename: Ji-Young
authors.initials: JY
authors.lastname: Hwang
authors.forename: Jung-In
authors.initials: JI
authors.lastname: Choi
authors.forename: Ji-Sook
authors.initials: JS
authors.lastname: Han
authors.forename: Hak-Ju
authors.initials: HJ
authors.lastname: Kim
authors.forename: You-Jin
authors.initials: YJ
authors.lastname: Jeon
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001786:Blood Glucose / Q000032:analysis; D002470:Cell Survival / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D042783:Endothelial Cells / Q000187:drug effects; D065089:Glycoside Hydrolase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D066298:In Vitro Techniques; D051379:Mice; D000459:Phaeophyceae / Q000737:chemistry*; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D019518:Postprandial Period; D014471:Umbilical Veins / Q000166:cytology; D000516:alpha-Amylases / Q000037:antagonists & inhibitors*
chemical_list: D001786:Blood Glucose; D065089:Glycoside Hydrolase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D007004:Hypoglycemic Agents; D010936:Plant Extracts; C513811:diphlorethohydroxycarmalol; D000516:alpha-Amylases